CymaBay Therapeutics, Inc. (CBAY) Stock: Why It’s Up

0

CymaBay Therapeutics, Inc. (CBAY) is gaining in the market today. The stock, focused on the biotech industry, is currently trading at $5.92 after heading up 6.47% so far in today’s session. As it relates to biotech stocks, there are a number of factors that have the ability to generate gains in the market. One of the most common is news. Here are the most recent trending headlines surrounding CBAY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-07-19 04:10PM CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug-05-19 08:00AM CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
Jul-31-19 04:23PM CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
Jun-18-19 08:00AM CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
Jun-17-19 02:15PM Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Nonetheless, any time investors are making an investing decision, investors should focus on far more than just news, especially in the highly speculative biotechnology industry. Here’s what’s happening in regard to CymaBay Therapeutics, Inc..

Trends That We’ve Seen From CBAY

While a move toward the top in a single session, like the move that we’re seeing from CymaBay Therapeutics, Inc. may make some investors excited, that alone shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s always smart to take a look at trends for a period longer than a single trading session. As it relates to CBAY, here are the trends that investors have experienced:

  • Past Seven Days – Over the past 7 days, CBAY has generated a change in value amounting to -3.58%.
  • Monthly – The monthly performance from CymaBay Therapeutics, Inc. works out to -14.45%.
  • Quarterly – Throughout the past quarter, the company has produced a return on investment of -54.04%
  • Past 6 Months – In the previous 6 months, we’ve seen a performance that works out to -34.66% from the stock.
  • Year To Date – Since the the last trading session of last year CBAY has generated a return on investment of -24.78%.
  • Full Year – Lastly, over the past year, investors have seen performance that works out to -48.07% from CBAY. Over this period of time, the stock has sold at a high of -57.71% and a low of 22.82%.

Ratios That Are Notable

Digging into various ratios associated with a company generally gives prospective investors a look of just how dangerous and/or rewarding a stock pick may be. Here are some of the key ratios to consider when looking at CBAY.

Short Ratio – The short ratio is a tool that is used by investors to measure the amount of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. Throughout the sector, biotech stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, when it comes to CymaBay Therapeutics, Inc., the stock’s short ratio comes to 6.10.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Essentially, they measure whether or not a company can cover its debts when they come due based on quick assets or current assets. In the biotechnology industry, many companies rely heavily on the continuation of support from investors, the quick and current ratios can look bad. However, quite a few good picks in the biotechnology sector do have good current and quick ratios. When it comes to CBAY, the quick and current ratios work out to 18.70 and 18.70 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. In this particular case, that ratio equates to 4.16.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is an important ratio to think about. In terms of CBAY, the cash to share value ratio works out to 3.80.

What Analysts Think About CymaBay Therapeutics, Inc.

While it’s rarely a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a smart idea to use their analysis to validate your own before making an investment decision in the biotechnology space. Below are the most recent moves that we have seen from analysts when it comes to CBAY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-25-19 Initiated Stifel Buy
Jun-12-19 Upgrade Raymond James Outperform → Strong Buy
May-14-19 Initiated Citigroup Buy $21
Feb-06-19 Initiated B. Riley FBR Neutral $9
Jun-28-18 Initiated Raymond James Outperform

Is Big Money Interested in CymaBay Therapeutics, Inc.?

An interesting fact that I’ve come to understand in my brief period alive, or somewhat alive has been that smart money tends to follow big money. So, investors that want to keep the risk down will follow trades made by institutions and insiders of the company. With that said, where is the big money when it comes to CBAY? Here’s the scoop:

  • Institutions – Currently, institutions own 88.51% of CymaBay Therapeutics, Inc.. On the other hand, it is worth noting that the ownership held by institutions has seen a move of 5.94% in the last quarter.
  • Insider Moves – with regard to insiders, insiders of the company currently own 0.74% of the company. Insider ownership of the company has seen a change of 0.00% throughout the past quarter.

What’s Going On With Share Counts?

Investors seem to have an interest in the total numbers of shares both available and outstanding. In regard to CymaBay Therapeutics, Inc., there are currently 69.60M with a float of 64.00M. These numbers mean that of the total of 69.60M shares of CBAY currently in existence today, 64.00M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CBAY, the short percent of the float is 13.26%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.57. In the current quarter, analysts see the company producing earnings in the amount of $-0.37. Over the last 5 years, CBAY has generated revenue in the amount of $0 with earnings coming in at -15.50%. On a quarter over quarter basis, earnings have seen movement of -17.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play an important role in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here